HEPIUS Flibanserin CAS:167933-07-5
Flibanserin is a non-hormonal prescription medication originally developed as an antidepressant but later repurposed to treat hypoactive sexual desire disorder (HSDD) in premenopausal women. Marketed under the brand name Addyi, Flibanserin addresses sexual dysfunction by targeting neurotransmitters in the brain rather than relying on hormonal changes.
Introduction to Flibanserin
Flibanserin is a non-hormonal prescription medication originally developed as an antidepressant but later repurposed to treat hypoactive sexual desire disorder (HSDD) in premenopausal women. Marketed under the brand name Addyi, Flibanserin addresses sexual dysfunction by targeting neurotransmitters in the brain rather than relying on hormonal changes. Approved by the U.S. Food and Drug Administration (FDA) in 2015, it is the first medication specifically indicated for the treatment of low sexual desire in women.
Chemical Structure and Properties
●Chemical Name: Flibanserin
●Molecular Formula: C20H21F3N4O
●Molecular Weight: 390.41 g/mol
●CAS Number: 167933-07-5
●Appearance: White to off-white crystalline powder
Flibanserin's structure allows it to interact with serotonin receptors in the brain, which play a crucial role in mood and desire regulation. Its distinct non-hormonal mechanism sets it apart from male-oriented erectile dysfunction treatments.
Mechanism of Action
Flibanserin functions as a serotonin 1A receptor agonist and serotonin 2A receptor antagonist. By balancing serotonin, dopamine, and norepinephrine levels in the brain, Flibanserin enhances sexual desire while reducing inhibitory responses. Its dual mechanism supports increased dopamine and norepinephrine activity (linked to sexual excitement) while reducing serotonin levels (associated with sexual inhibition).
Applications
Flibanserin is primarily prescribed for:
●Hypoactive Sexual Desire Disorder (HSDD): A condition characterized by persistent low sexual desire that causes significant distress in premenopausal women.
●Off-label Uses: Some studies have explored Flibanserin's potential in addressing sexual dysfunction in postmenopausal women and other mood disorders. However, off-label use should only be attempted under medical supervision.
Benefits
●Increased Sexual Desire: Clinical trials have shown a notable improvement in sexual desire among women with HSDD.
●Improved Emotional Well-being: Enhanced mood, confidence, and relationship satisfaction are often reported.
●Non-Hormonal Approach: Flibanserin is suitable for women who cannot or prefer not to use hormonal therapies.
●FDA-Approved Treatment: Ensures the product has undergone rigorous safety and efficacy evaluations.
Dosage and Administration
●Standard Dosage: The recommended dosage for Flibanserin is 100 mg taken once daily at bedtime. Administering the medication before sleep reduces the risk of side effects such as dizziness, fatigue, or low blood pressure.
●Time to Notice Effects: Improvement may be observed within 4 to 8 weeks of consistent use.
●Missed Dose: If a dose is missed, it should be skipped rather than taken later to avoid potential overdose effects.
Cycle and Usage Guidelines
●Cycle Duration: Flibanserin is intended for continuous daily use rather than a traditional "on-off" cycle. Consistency is crucial for sustained effects.
●Assessment Period: Medical professionals recommend evaluating the drug's efficacy after 8 weeks. If no improvement is noted, discontinuation is advisable.
Half-Life and Metabolism
●Half-Life: Flibanserin has a half-life of approximately 11 hours, ensuring gradual release and consistent therapeutic effects when taken daily.
●Metabolism: It is metabolized primarily in the liver via the CYP3A4 enzyme pathway, with its inactive metabolites excreted through urine and feces.
●Bioavailability: Flibanserin's absorption is improved when taken with food; however, consuming alcohol during treatment is strictly discouraged due to heightened risks of dizziness, fainting, and hypotension.
Post-Cycle Therapy (PCT)
Although Flibanserin does not involve hormonal manipulation like anabolic steroids, cessation may still lead to psychological effects in some users. A tailored post-cycle strategy may include:
●Emotional Support: Cognitive-behavioral therapy (CBT) or counseling can help address emotional concerns post-treatment.
●Lifestyle Adjustments: Regular exercise, balanced nutrition, and improved sleep quality can support ongoing sexual health.
●Medical Guidance: Consulting a healthcare professional ensures the safest discontinuation process.
Potential Side Effects
While Flibanserin is generally well-tolerated, some side effects may occur, including:
●Dizziness or Lightheadedness
●Nausea and Vomiting
●Fatigue or Drowsiness
●Dry Mouth
●Hypotension (low blood pressure)
●Fainting (especially if combined with alcohol)
Severe side effects are rare but may include significant drops in blood pressure or unconsciousness. To minimize risks, users should adhere strictly to dosage guidelines and avoid alcohol.
Contraindications and Precautions
Flibanserin may not be suitable for individuals with:
●Liver Impairment (due to its hepatic metabolism)
●Current Alcohol Use Disorder
●Concurrent Use of CYP3A4 Inhibitors (e.g., certain antibiotics, antifungals, or antivirals)
●Pregnancy and Breastfeeding (safety in these populations has not been confirmed)
Interactions
Flibanserin may interact negatively with:
●Alcohol (heightened risk of syncope)
●CNS Depressants (e.g., benzodiazepines, opioids)
●Certain Antifungals or Antibiotics that inhibit CYP3A4 pathways
Patients should disclose their full medical history and medication regimen to their healthcare provider before starting Flibanserin.
Lifestyle Recommendations
To maximize Flibanserin's efficacy and minimize side effects:
●Maintain a consistent bedtime routine.
●Avoid alcohol and other CNS depressants.
●Adopt stress-reducing activities such as meditation or yoga to support mental well-being.
Clinical Data
| Brand |
HEPIUS |
|
Trade names |
Addyi,Flibanserin |
|
CAS |
167933-07-5 |
|
Molar mass |
390.40 |
|
Formula |
C20H21F3N4O |
|
Purity |
Above 98% |
|
Apprarance |
100mg*30 |
Any needs, please contact us
Email: Jasonraws106@gmail.com
WhatsApp: +86-15572565525
Telegram: +86-19128233885
Conclusion
Flibanserin offers a groundbreaking solution for women experiencing hypoactive sexual desire disorder. Its unique mechanism, targeting brain neurotransmitters rather than hormones, provides a non-hormonal treatment alternative. By following appropriate dosage guidelines, monitoring side effects, and incorporating lifestyle adjustments, users can achieve optimal benefits while ensuring safety. For individuals considering Flibanserin, professional medical consultation remains essential to ensure suitability and maximize positive outcomes.
Hot Tags: HEPIUS Flibanserin CAS:167933-07-5, China HEPIUS Flibanserin CAS:167933-07-5 manufacturers, suppliers, factory
